| dbo:abstract
|
- Rovelizumab, also known as LeukArrest and Hu23F2G, is a humanized monoclonal antibody which was an experimental immunosuppressive drug. Rovelizumab was developed by Icos to treat patients with haemorrhagic shock. The drug is a monoclonal antibody that suppresses white blood cells which become overly active during shock. During testing the number of patients given the drug was low because rovelizumab had to be delivered within four hours of the injury and consent was required. Often the patient was unconscious and relatives had to be reached to give consent. In June 1998, Icos and many medical centers asked the United States Food and Drug Administration (FDA) to waive consent requirements in situations where the patient was at high risk of dying and relatives could not be reached. While some medical ethicists opposed waiving consent, the FDA approved the proposal in August 1998 for five medical centers. Development of rovelizumab was halted in April 2000 when interim data from phase III clinical trials did not meet Icos's goals. The company's goals for rovelizumab included reducing the chance of multiple organ failure and reducing the death-rate from shock at 28 days. Rovelizumab was also being tested for treating heart attack, multiple sclerosis, and stroke, and was being explored as a treatment for cerebral vasospasm, head trauma, kidney transplantation, and restenosis. Multiple companies have tried to develop anti-CD18 drugs, but none of them have been successful. Among them are Genentech's erlizumab, and two drugs developed by Protein Design Labs and Centocor. Although trials in humans have not gone well, the research of anti-CD18 drugs in animals has been encouraging. It is thought that the experimental medicines are affecting the lymphocyte adhesion pathway in humans in unintended ways. (en)
- Il rovelizumab, noto anche come LeukArrest o Hu23F2G, è un anticorpo monoclonale umanizzato, che è stato usato sperimentalmente come farmaco immunosoppressivo. Il rovelizumab è stato sviluppato dalla per il trattamento di pazienti con shock emorragico. Il farmaco è un anticorpo monoclonale che sopprime i globuli bianchi che diventano iper-attivi in corso di shock. Il numero di pazienti trattati con il farmaco, nelle sperimentazioni effettuate, è stato bassoperché il rovelizumab va somministrato nelle prima 4 ore dall'evento scatenante lo shock. L'obbigo di ottenere il consenso informato da parte dei pazienti e/o parenti rende difficile l'arruolamento dei pazienti stessi, a causa dei tempi troppo brevi disponibili per l'efficacia clinica del farmaco. Il rovelizumab è stato anche studiato per il trattamento dell'attacco di cuore (infarto), nella sclerosi multipla, e dell'ictus, ed è in fase di studio come trattamento del vasospasmo cerebrale, nel trauma cranico, e nel trapianto renale e nella . Altre aziende hanno cercato di sviluppare farmaci anticorpi monoclonali anti-CD18, tra questi ci sono la Genentech con erlizumab, la (PDL) e la con due loro farmaci. Anche se le prove sperimentali sull'uomo sono state deludenti, la ricerca di farmaci ad azione anti-CD18 negli animali è stata incoraggiante.L'inefficacia si pensa sia dovuta al fatto che questi farmaci sperimentali influenzano in modo casuale il meccanismo di adesione dei linfociti negli esseri umani. (it)
|
| rdfs:comment
|
- Rovelizumab, also known as LeukArrest and Hu23F2G, is a humanized monoclonal antibody which was an experimental immunosuppressive drug. Rovelizumab was developed by Icos to treat patients with haemorrhagic shock. The drug is a monoclonal antibody that suppresses white blood cells which become overly active during shock. During testing the number of patients given the drug was low because rovelizumab had to be delivered within four hours of the injury and consent was required. Often the patient was unconscious and relatives had to be reached to give consent. In June 1998, Icos and many medical centers asked the United States Food and Drug Administration (FDA) to waive consent requirements in situations where the patient was at high risk of dying and relatives could not be reached. While som (en)
- Il rovelizumab, noto anche come LeukArrest o Hu23F2G, è un anticorpo monoclonale umanizzato, che è stato usato sperimentalmente come farmaco immunosoppressivo. Il rovelizumab è stato sviluppato dalla per il trattamento di pazienti con shock emorragico. Il farmaco è un anticorpo monoclonale che sopprime i globuli bianchi che diventano iper-attivi in corso di shock. Altre aziende hanno cercato di sviluppare farmaci anticorpi monoclonali anti-CD18, tra questi ci sono la Genentech con erlizumab, la (PDL) e la con due loro farmaci. (it)
|
